Abstract
Cancer cell heterogeneity is a common feature - both between patients diagnosed with the same cancer and within an individual patient’s tumor - and leads to widely different response rates to cancer therapies and the potential for the emergence of drug resistance. Diverse therapeutic approaches have been developed to combat the complexity of cancer, including individual treatment modalities designed to target tumor heterogeneity. This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations. Strategies that allow for combination of prodrug-activation gene therapy with a novel replication-conditional, heterogeneous tumor-targeting adenovirus are discussed, as are the benefits of using adenoviral vectors as tumor-targeting oncolytic vectors. While the anticancer activity of many adenoviral vectors has been well established in preclinical studies, only limited successes have been achieved in the clinic, indicating a need for further improvements in activity, specificity, tumor cell delivery and avoidance of immunogenicity.
Keywords: Cancer gene therapy, cytochrome P450 prodrug activation, replication-conditional adenovirus, oncolytic adenovirus, tumor heterogeneity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer
Volume: 14 Issue: 1
Author(s): Joshua C. Doloff and David J. Waxman
Affiliation:
Keywords: Cancer gene therapy, cytochrome P450 prodrug activation, replication-conditional adenovirus, oncolytic adenovirus, tumor heterogeneity.
Abstract: Cancer cell heterogeneity is a common feature - both between patients diagnosed with the same cancer and within an individual patient’s tumor - and leads to widely different response rates to cancer therapies and the potential for the emergence of drug resistance. Diverse therapeutic approaches have been developed to combat the complexity of cancer, including individual treatment modalities designed to target tumor heterogeneity. This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations. Strategies that allow for combination of prodrug-activation gene therapy with a novel replication-conditional, heterogeneous tumor-targeting adenovirus are discussed, as are the benefits of using adenoviral vectors as tumor-targeting oncolytic vectors. While the anticancer activity of many adenoviral vectors has been well established in preclinical studies, only limited successes have been achieved in the clinic, indicating a need for further improvements in activity, specificity, tumor cell delivery and avoidance of immunogenicity.
Export Options
About this article
Cite this article as:
Doloff C. Joshua and Waxman J. David, Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990309
DOI https://dx.doi.org/10.2174/18715206113139990309 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Attenuating Muscle Wasting: Cell and Gene Therapy Approaches
Current Genomics Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Current Cancer Drug Targets CYLD-Mediated Signaling and Diseases
Current Drug Targets Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Regulatory Role of the α7nAChR in Cancer
Current Drug Targets Hybridized Quinoline Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and Molecular Docking
Anti-Cancer Agents in Medicinal Chemistry Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting
Current Pharmaceutical Design A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics
Current Cancer Therapy Reviews PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
Current Cancer Drug Targets Radiotracers in Oncology
Current Radiopharmaceuticals Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Targeting the p53 Pathway of Apoptosis
Current Pharmaceutical Design Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Peptimmunology: Immunogenic Peptides and Sequence Redundancy
Current Drug Discovery Technologies